DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

BAX·Baxter International Inc.

$.
+. (+.%)
After Hours
High
$22.79
Open
$22.64
Market Cap
11.67B
52W High
$31.15
Low
$22.34
P. Close
$22.62
P/E
-
52W Low
$15.73
Fwd P/E
11.25
DailyIQ Est.
$18.86
Technical Score (1D)
86
BUY
News Sentiment
47
MIXED
Baxter International’s latest outlook signals a sharp slowdown in growth, with constant‑currency revenue falling short of industry peers and earnings per share declining 7.2 % annually. The company’s aggressive expansion has produced negative returns on capital, indicating that recent investments are eroding shareholder value. This combination of weak top‑line momentum and capital inefficiency suggests the stock is likely to underperform its peers over the next 1–10 trading days. Investors should therefore remain cautious and monitor how the firm adjusts its capital allocation strategy. A key watch item is whether Baxter will shift focus toward product innovation or cost‑control initiatives to reverse the earnings decline. The company’s upcoming earnings guidance will also reveal whether it plans to cut discretionary spending or raise capital to fund new projects. Analysts will look for any sign that the firm is tightening its balance sheet or accelerating product launches to regain growth. If Baxter announces a new product pipeline or a strategic partnership, that could mitigate the current value erosion narrative. Finally, any change in the company’s dividend policy or share buyback plans will be a critical indicator of how management intends to return capital to shareholders.
Earnings Summary
Baxter International Inc. is a global healthcare company that designs and manufactures a broad portfolio of sterile intravenous solutions, infusion systems, and essential pharmaceuticals, serving hospitals and other medical settings worldwide. Operating within the medical instruments and supplies sector, Baxter leverages a multi‑channel distribution network to deliver life‑sustaining products across diverse healthcare environments. In the most recent two quarters, Baxter reported revenue of $2.974 billion in Q4 2025 and $2.701 billion in Q1 2026, a decline from the $2.810 billion and $2.835 billion seen in Q2 and Q3 2025, respectively; EPS fell from $0.69 in Q3 2025 to $0.44 in Q4 2025 and further to $0.36 in Q1 2026, yet the company still beat consensus estimates in each of those periods (0.44 vs 0.328 and 0.36 vs 0.311). Historically, Baxter has maintained a pattern of EPS beats in five of the last six quarters, even as revenue has fluctuated, indicating resilient profitability amid market shifts. Recent institutional activity, highlighted by Thompson Siegel & Walmsley’s purchase of additional shares, signals renewed confidence in Baxter’s growth prospects, while a Citigroup downgrade to “Sell” introduces a more cautious tone; the stock’s recent 10.9% weekly rally underscores heightened volatility. Going forward, investors should watch for the company’s Q2 2026 guidance, particularly any updates on revenue targets and EPS expectations, as well as potential changes in institutional ownership and regulatory developments that could influence demand for Baxter’s medical devices. Additionally, analysts will monitor any updates to the company’s supply‑chain initiatives that could influence cost structures.

EPS

EstBeatMiss
$0.25$0.38$0.50$0.62$0.75Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.37 - -
Q1'26$0.31$0.36+15.7%
Q4'25$0.33$0.44+34.0%
Q3'25$0.60$0.69+15.4%
Q2'25$0.61$0.54-11.5%
Q1'25$0.48$0.55+13.8%

Revenue

EstBeatMiss
$2.5B$2.7B$2.8B$2.9B$3.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.8B - -
Q1'26$2.6B$2.7B+2.1%
Q4'25$2.6B$3.0B+14.2%
Q3'25 - $2.8B -
Q2'25 - $2.8B -
Q1'25 - $2.6B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BAX Stock Snapshot

BAX is currently trading at $22.38, giving Baxter International Inc. a market cap of 11.67B. Today's range spans $22.34–$22.79, with shares opening at $22.64 and moving down $0.24 (1.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 47/100.

Over the past year BAX has traded between $15.73 and $31.15 - the current price is +42.3% off the 52-week low and -28.2% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $21.71 (range $17.00–$40.00), implying downside of -3.0%.

Cross-asset context supports the bullish read on BAX: when Healthcare sector conditions are favorable, large-cap names with 86/100 technical scores (BUY) and neutral sentiment (47/100) outperform on a risk-adjusted basis. Price: $22.38 (in the middle of its 52-week range). The 52-week context of $15.73–$31.15 shows the full trading history - and the current setup is one of the stronger entries within that range. At 11.67B in market cap, position sizing is the key variable, not the direction.

What makes BAX's BUY setup (86/100) particularly actionable at 11.67B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $22.38 (in the middle of its 52-week range in $15.73–$31.15), with sentiment running neutral at 47/100, the setup rewards conviction-sized positioning more than it does speculative small bets.